Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Operating Leases (2019 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Operating Leases for 8 consecutive years, with $13.9 million as the latest value for Q1 2026.

  • For Q1 2026, Operating Leases rose 431.77% year-over-year to $13.9 million; the TTM value through Mar 2026 reached $13.9 million, up 431.77%, while the annual FY2025 figure was $14.1 million, 253.28% up from the prior year.
  • Operating Leases hit $13.9 million in Q1 2026 for Bicycle Therapeutics, down from $14.1 million in the prior quarter.
  • Across five years, Operating Leases topped out at $14.4 million in Q1 2023 and bottomed at $981000.0 in Q3 2025.
  • Average Operating Leases over 5 years is $9.0 million, with a median of $10.4 million recorded in 2023.
  • Year-over-year, Operating Leases plummeted 82.27% in 2025 and then soared 431.77% in 2026.
  • Bicycle Therapeutics' Operating Leases stood at $10.9 million in 2022, then fell by 13.81% to $9.4 million in 2023, then plummeted by 57.47% to $4.0 million in 2024, then skyrocketed by 253.28% to $14.1 million in 2025, then decreased by 1.57% to $13.9 million in 2026.
  • According to Business Quant data, Operating Leases over the past three periods came in at $13.9 million, $14.1 million, and $981000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.